FDA clears AI-powered heart failure tool developed at Mayo Clinic

An artificial intelligence-powered solution for heart failure developed at Rochester, Minn.-based Mayo Clinic has received FDA clearance.

Advertisement

The EchoGo Heart Failure tool was created by Ultromics, a spinoff of the University of Oxford in the U.K. in collaboration with Mayo Clinic. It uses AI to detect heart failure with reduced ejection fraction, or HFpEF, from a single electrocardiogram image, aiming to expedite care.

“HFpEF currently is associated with high rates of hospitalization and mortality,” Patricia Pellikka, MD, vice chair of cardiovascular medicine at Mayo Clinic, said in a Dec. 6 Ultromics news release. “By facilitating early diagnosis and treatment, we can improve the lives of many.”

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Innovation

Advertisement

Comments are closed.